Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin

Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM). This study further investigated the relationship between pioglitazone use and the risk of developing Alzheimer's disease (AD) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hsin-Chung, Chung, Chi-Hsiang, Chen, Lih-Chyang, Wang, Jui-Yang, Chen, Chien-Chou, Huang, Kuo-Yang, Tsai, Ming-Hang, Chien, Wu-Chien, Lin, Hsin-An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126143/
https://www.ncbi.nlm.nih.gov/pubmed/37095270
http://dx.doi.org/10.1038/s41598-023-33674-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126143/
https://www.ncbi.nlm.nih.gov/pubmed/37095270
http://dx.doi.org/10.1038/s41598-023-33674-2

Ejemplares similares